Medtronic price target raised to $96 from $92 at Truist

Truist raised the firm’s price target on Medtronic (MDT) to $96 from $92 and keeps a Hold rating on the shares. The company’s in-line Q1 organic revenue growth saw PFA upside offset by US Diabetes and Specialty Therapies weakness, the analyst tells investors in a research note. Truist adds that while it is more constructive on Medtronic’s more durable and profitable growth narrative, it’s unclear how and when activism will enhance execution.